ARANESP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARANESP (ARANESP).
Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
| Metabolism | Darbepoetin alfa is a recombinant protein. Its metabolism is not fully characterized but is expected to undergo proteolytic degradation into small peptides and amino acids. No specific metabolic pathways or enzymes have been identified. |
| Excretion | Renal clearance accounts for approximately 10% of total body clearance; however, darbepoetin alfa is primarily eliminated via receptor-mediated endocytosis and subsequent intracellular degradation. Less than 5% is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life is approximately 21 hours (range 15-30 hours) in patients with chronic kidney disease following intravenous administration, and 49 hours (range 27-89 hours) after subcutaneous administration. The long half-life allows for less frequent dosing compared to epoetin alfa. |
| Protein binding | Approximately 50% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Vd is approximately 0.07 L/kg (range 0.04-0.10 L/kg), indicating limited distribution predominantly within the vascular and extracellular fluid compartments. |
| Bioavailability | Subcutaneous: Approximately 37% (range 30-50%) relative to intravenous administration. |
| Onset of Action | Subcutaneous: Reticulocyte count increases within 1 week, with hemoglobin rise noted typically after 2-6 weeks. Intravenous: Similar onset, with initial effects on reticulocytes within 5-7 days. |
| Duration of Action | Clinical effects on hemoglobin levels persist for 7-14 days post-dose, supporting once-weekly or once-every-2-week dosing intervals. The pharmacodynamic effect (erythropoiesis) lasts longer than the drug's residence time due to receptor-mediated clearance. |
Initial dose 0.45 mcg/kg intravenously or subcutaneously once weekly; for patients converting from epoetin alfa, see prescribing information for dose conversion.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment recommended for GFR ≥60 mL/min/1.73 m2; for GFR <60 mL/min/1.73 m2, no adjustment needed as drug is not renally eliminated, but monitor hemoglobin closely. |
| Liver impairment | No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to limited data. |
| Pediatric use | For pediatric patients (≥1 year) on dialysis: starting dose 0.45 mcg/kg intravenously or subcutaneously once weekly; adjust to maintain hemoglobin target of 9-10.5 g/dL. |
| Geriatric use | No specific dose adjustment; use lowest effective dose to avoid excessive hemoglobin levels (risk of thromboembolic events). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARANESP (ARANESP).
| Breastfeeding | Unknown if excreted in human milk; M/P ratio not determined. Weigh benefits against potential risks to infant. |
| Teratogenic Risk | Animal studies show no evidence of teratogenicity in rats and rabbits at doses up to 150 mcg/kg. No adequate human studies in pregnancy. Use only if potential benefit justifies potential risk to fetus. |
| Fetal Monitoring | Monitor hemoglobin weekly until stable, then monthly; assess blood pressure; monitor for thrombosis; fetal monitoring as per standard obstetrical practice. |
■ FDA Black Box Warning
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS, AND TUMOR PROGRESSION OR RECURRENCE. Use the lowest dose sufficient to avoid red blood cell transfusion. ESAs increased the risk of death and serious cardiovascular events in clinical trials when targeting hemoglobin levels >11 g/dL. ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, use the lowest dose needed to avoid red blood cell transfusions.
| Common Effects | Application site reactions burning irritation itching and redness |
| Serious Effects |
["Uncontrolled hypertension.","History of serious allergic reactions to darbepoetin alfa or any product components.","Pure red cell aplasia (PRCA) following erythropoietin therapy."]
| Precautions | ["Increased mortality, serious cardiovascular events, and thromboembolic events when targeting hemoglobin >11 g/dL.","Increased risk of tumor progression or recurrence in cancer patients.","Hypertension: monitor blood pressure closely; treat adequately.","Seizures: increased risk in patients with CKD.","Pure red cell aplasia (PRCA) and severe anemia with neutralizing antibodies to erythropoietin; discontinue if suspected.","Risk of serious allergic reactions including anaphylaxis.","Increased risk of thrombotic events including venous thromboembolism and vascular access thrombosis.","Monitor hemoglobin weekly until stable, then periodically."] |
Loading safety data…
| Fertility Effects | No adverse effects on fertility observed in animal studies; no human data available. |
| Food/Dietary | No known food interactions. Avoid alcohol due to potential interference with erythropoiesis and iron metabolism. Maintain adequate dietary intake of iron, vitamin B12, and folate. |
| Clinical Pearls | Darbepoetin alfa has a longer half-life than epoetin alfa, allowing for less frequent dosing (every 1-2 weeks vs. 1-3 times weekly). Monitor hemoglobin weekly until stable, then monthly; target Hb 10-12 g/dL. Do not use to treat anemia of chronic disease or cancer-related anemia in patients not receiving chemotherapy. Increased risk of thrombosis, especially if Hb exceeds 12 g/dL. Pure red cell aplasia (PRCA) can occur with neutralizing antibodies; discontinue and do not switch to another erythropoiesis-stimulating agent. Ensure adequate iron stores (ferritin >100 ng/mL, TSAT >20%) before and during therapy. |
| Patient Advice | This medication helps your body make more red blood cells to treat anemia. · It is given as an injection under the skin or into a vein, usually once every 1 to 2 weeks. · Do not shake the vial; store it in the refrigerator and protect from light. · Report symptoms of blood clots such as leg pain, chest pain, sudden shortness of breath, or vision changes. · You will need regular blood tests to check your hemoglobin levels and iron stores. · Do not use this medicine if you have high blood pressure that is not well controlled. · Take iron supplements as prescribed to help the medicine work effectively. |